Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02142920 | Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers | PHASE1 | COMPLETED | 6 | — | — | Jul 1, 2014 | Aug 1, 2014 | Sep 4, 2014 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| [14C] PF 05212384 | EXPERIMENTAL | Receive PF-05212384 89 mg Dose |
| Name | Type | Description |
|---|---|---|
| PF-05212384 | DRUG | Single 89 mg Dose via 30 minute IV infusion |
Inclusion Criteria: * Healthy male subjects between the ages of 30- 65 years vasectomised or \>40 with no desire to father children in the near future (12 months), inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examinati...